Get started
Author

Joanne Cox

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
2020 · Stephen R. D. Johnston, Nadia Harbeck, et al. · Journal of Clinical Oncology · 1,047
PDF
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
2019 · Stephen Johnston, Miguel Martin, et al. · npj Breast Cancer · 684
PDF
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
2020 · Hope S. Rugo, Jens Huober, et al. · The Oncologist · 184
PDF
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia
2017 · Saroj Vadhan-Raj, Rafat Abonour, et al. · Journal of Hematology & Oncology · 89
PDF
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
2021 · Hope S. Rugo, Jens Huober, et al. · The Oncologist · 30
PDF
Abstract GS1-01: Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer
2021 · Joyce A. O'Shaughnessy, Stephen Johnston, et al. · Cancer Research · 13
Abstract P6-15-01: Analysis of renal function in MONARCH 1: A phase 2 study of abemaciclib, a CDK4 & 6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic breast cancer (MBC)
2017 · S Tolaney, AQ Lam, et al. · Cancer Research · 10
The association of early toxicity and outcomes for patients treated with abemaciclib.
2018 · Hope S. Rugo, George W. Sledge, et al. · Journal of Clinical Oncology · 8
Phase 1 Study of a Hepcidin Antagonist, LY2787106, in Cancer-Associated Anemia
2015 · Saroj Vadhan-Raj, Rafat Abonour, et al. · Blood · 6
Abstract CT040: MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2- advanced breast cancer - Results from the preplanned final PFS analysis
2018 · Matthew P. Goetz, Miguel Martin, et al. · Cancer Research · 3
2MO Abemaciclib in high risk early breast cancer
2020 · S. Johnston, N. Harbeck, et al. · Annals of Oncology · 2
PDF
LBA5_PR Abemaciclib in high risk early breast cancer
2020 · S.R.D. Johnston, N. Harbeck, et al. · Annals of Oncology · 2
PDF
Abstract OT2-02-02: MONARCH E: A phase 3 study of standard adjuvant endocrine therapy with or without abemaciclib in patients with high risk, node positive, hormone-receptor positive, human epidermal growth factor receptor 2-negative early-stage breast cancer
2020 · Priya Rastogi, Masakazu Toi, et al. · Cancer Research · 2
LBA 1 Baseline characteristics of patients from Asia enrolled in monarchE, evaluating abemaciclib in high risk early breast cancer
2020 · Z. Jiang, T. Nakayama, et al. · Annals of Oncology · 1
Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib plus adjuvant endocrine therapy for high-risk early breast cancer
2021 · M Reinisch, J O’Shaughnessy, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie
In Reply
2021 · Hope S. Rugo, Jens Huober, et al. · The Oncologist
PDF
Works count: 18
Citation count: 2,081
H-index: 8
I10-index: 7
Year
Topic
Type